Iniulat ng Allogene ang positibong interim futility data ng ALPHA3 para sa cema-cel

Inilalantad ng 8-K ang unang interim futility analysis mula sa pivotal Phase 2 ALPHA3 trial ng cema-cel sa 1L LBCL consolidation. Naabot ang MRD negativity sa 58.3% ng mga pasyenteng ginamot ng cema-cel kumpara sa 16.7% sa observation arm, kasama ang mabilis na ctDNA clearance at walang naiulat na CRS, ICANS, o GvHD. Nagpapatuloy ang trial nang nakatago para sa EFS, PFS, at OS endpoints, na may inaasahang buong enrollment sa katapusan ng 2027 at isang interim EFS analysis na binalak para sa kalagitnaan ng 2027.

Mahahalagang fact

Na-file: Abr 13, 2026, 11:45 AM
Kaganapan: Topline na resulta
Direksyon: Positibo
Kumpanya: ALLOAllogene
Asset: cemacabtagene ansegedleucel
Pinagmulan: SEC 8-K
Kumpiyansa: May source
Pansamantalang datos ng EFS: kalagitnaan ng 2027
Pangunahing datos ng EFS: kalagitnaan ng 2028
Mga lokasyon sa komunidad: isang-katlo
Target na pagpapatala: 220
Paglinis ng MRD (cema-cel): 58.3% (7/12)
Pagbabago ng ctDNA (grupong obserbasyon): +26.6%
Pagbawas ng ctDNA (cema-cel): 97.7%
Paglinis ng MRD (grupong obserbasyon): 16.7% (2/12)

Sipi mula sa source

8-K false 0001737287 0001737287 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 Allogene Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38693 82-3562771 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 210 East Grand Avenue South San Francisco , CA 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (650) 457-2700 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Fo

SEC 8-K